Dr. Tasha Lotus Lin, MD

Dr. Lin practices at UCLA Santa Monica Medical Center in Santa Monica, California, part of University of California Health.

Dr. Lin's NPI, 1912343674, was assigned on May 21, 2013. Dr. Lin graduated from University Of Michigan Medical School in 2013. Dr. Lin holds California license A141627.

Dr. Lin's primary practice is UCLA Santa Monica Medical Center, at 1250 16th Street, Santa Monica, CA 90404 in Los Angeles County. The practice phone is (310) 319-4000.

Dr. Lin's primary practice is UCLA Santa Monica Medical Center in Santa Monica, California, part of University of California Health. Dr. Lin is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Lin to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Lin is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Lin's licenses on file in 2 states: California and Minnesota.

Dmand AI lists breast cancer, chronic anemia, colorectal cancer and prostate cancer among the conditions Dr. Lin treats.

CMS data shows 1,941 Medicare services from Dr. Lin across 26 procedure codes in 2024, for 322 Medicare patients. Medicare paid $75,842 for them.

CMS counts 322 Medicare patients who saw Dr. Lin in 2024. The largest group is 65 to 74, with 144 patients. 72% of them have high blood pressure, and 71% have high cholesterol. 18% are also on Medicaid. Their average risk score is 2.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 64, with 53% women.

In 2024, Dr. Lin wrote 218 Medicare Part D claims for 42 patients. 75% of them were for generic drugs. CMS names the drug for 111 of them, across 5 drugs with 11 or more claims each, at $264,085 in total drug cost. In 2023, CMS named 31 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Lin for performance year 2024, reported as part of a group. Dr. Lin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lin as offering telehealth.

Dmand AI links 3 papers to Dr. Lin, published from 2013 to 2024. Dr. Lin's most frequent co-authors are Stephen M. Ansell, MD, Douglas B. Chepeha, MD and Steven Bennett Chinn, MD.

CMS Open Payments shows 14 general payments to Dr. Lin from 3 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 72% of the total. Janssen Pharmaceuticals, Inc paid the most, $135.

Dr. Lin graduated from University Of Michigan Medical School in 2013.

Dr. Lin is in network with 16 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.